vs
玛斯特锁（MBC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是玛斯特锁的1.2倍（$772.1M vs $644.6M），Revvity净利率更高（12.7% vs -6.5%，领先19.3%），Revvity同比增速更快（5.9% vs -3.5%），Revvity自由现金流更多（$161.8M vs $52.5M），过去两年Revvity的营收复合增速更高（9.0% vs 0.5%）
玛斯特锁是美国知名安防产品供应商，1921年由锁匠发明家哈里·索雷夫创立，总部位于威斯康星州奥克里克，主营挂锁、密码锁、保险箱及相关安防产品，现为富俊创新集团旗下子公司，在全球安防锁具领域拥有较高的市场认可度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MBC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$644.6M
营收增速更快
RVTY
高出9.3%
-3.5%
净利率更高
RVTY
高出19.3%
-6.5%
自由现金流更多
RVTY
多$109.3M
$52.5M
两年增速更快
RVTY
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $644.6M | $772.1M |
| 净利润 | $-42.0M | $98.4M |
| 毛利率 | 26.0% | — |
| 营业利润率 | -4.2% | 14.5% |
| 净利率 | -6.5% | 12.7% |
| 营收同比 | -3.5% | 5.9% |
| 净利润同比 | -400.0% | 3.9% |
| 每股收益（稀释后） | $-0.32 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MBCRVTY
| Q4 25 | $644.6M | $772.1M | ||
| Q3 25 | $698.9M | $698.9M | ||
| Q2 25 | $730.9M | $720.3M | ||
| Q1 25 | $660.3M | $664.8M | ||
| Q4 24 | $667.7M | $729.4M | ||
| Q3 24 | $718.1M | $684.0M | ||
| Q2 24 | $676.5M | $691.7M | ||
| Q1 24 | $638.1M | $649.9M |
净利润MBCRVTY
| Q4 25 | $-42.0M | $98.4M | ||
| Q3 25 | $18.1M | $46.7M | ||
| Q2 25 | $37.3M | $53.9M | ||
| Q1 25 | $13.3M | $42.2M | ||
| Q4 24 | $14.0M | $94.6M | ||
| Q3 24 | $29.1M | $94.4M | ||
| Q2 24 | $45.3M | $55.4M | ||
| Q1 24 | $37.5M | $26.0M |
毛利率MBCRVTY
| Q4 25 | 26.0% | — | ||
| Q3 25 | 31.2% | 53.6% | ||
| Q2 25 | 32.8% | 54.5% | ||
| Q1 25 | 30.6% | 56.5% | ||
| Q4 24 | 30.4% | — | ||
| Q3 24 | 33.1% | 56.3% | ||
| Q2 24 | 34.1% | 55.7% | ||
| Q1 24 | 32.1% | 54.6% |
营业利润率MBCRVTY
| Q4 25 | -4.2% | 14.5% | ||
| Q3 25 | 6.0% | 11.7% | ||
| Q2 25 | 9.2% | 12.6% | ||
| Q1 25 | 5.6% | 10.9% | ||
| Q4 24 | 5.6% | 16.3% | ||
| Q3 24 | 8.0% | 14.3% | ||
| Q2 24 | 11.5% | 12.4% | ||
| Q1 24 | 9.8% | 6.8% |
净利率MBCRVTY
| Q4 25 | -6.5% | 12.7% | ||
| Q3 25 | 2.6% | 6.7% | ||
| Q2 25 | 5.1% | 7.5% | ||
| Q1 25 | 2.0% | 6.4% | ||
| Q4 24 | 2.1% | 13.0% | ||
| Q3 24 | 4.1% | 13.8% | ||
| Q2 24 | 6.7% | 8.0% | ||
| Q1 24 | 5.9% | 4.0% |
每股收益（稀释后）MBCRVTY
| Q4 25 | $-0.32 | $0.86 | ||
| Q3 25 | $0.14 | $0.40 | ||
| Q2 25 | $0.29 | $0.46 | ||
| Q1 25 | $0.10 | $0.35 | ||
| Q4 24 | $0.10 | $0.77 | ||
| Q3 24 | $0.22 | $0.77 | ||
| Q2 24 | $0.35 | $0.45 | ||
| Q1 24 | $0.29 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $183.3M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $3.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MBCRVTY
| Q4 25 | $183.3M | $919.9M | ||
| Q3 25 | $114.8M | $931.4M | ||
| Q2 25 | $120.1M | $991.8M | ||
| Q1 25 | $113.5M | $1.1B | ||
| Q4 24 | $120.6M | $1.2B | ||
| Q3 24 | $108.4M | $1.2B | ||
| Q2 24 | $189.4M | $2.0B | ||
| Q1 24 | $153.7M | $1.7B |
总债务MBCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MBCRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.3B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产MBCRVTY
| Q4 25 | $3.1B | $12.2B | ||
| Q3 25 | $3.0B | $12.1B | ||
| Q2 25 | $3.0B | $12.4B | ||
| Q1 25 | $3.0B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $3.0B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.4B | $13.4B |
负债/权益比MBCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.79× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $86.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $52.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.1% | 21.0% |
| 资本支出强度资本支出/营收 | 5.3% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $117.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MBCRVTY
| Q4 25 | $86.9M | $182.0M | ||
| Q3 25 | $55.4M | $138.5M | ||
| Q2 25 | $84.8M | $134.3M | ||
| Q1 25 | $-31.4M | $128.2M | ||
| Q4 24 | $115.1M | $174.2M | ||
| Q3 24 | $80.8M | $147.9M | ||
| Q2 24 | $77.4M | $158.6M | ||
| Q1 24 | $18.7M | $147.6M |
自由现金流MBCRVTY
| Q4 25 | $52.5M | $161.8M | ||
| Q3 25 | $39.5M | $120.0M | ||
| Q2 25 | $66.7M | $115.5M | ||
| Q1 25 | $-41.2M | $112.2M | ||
| Q4 24 | $68.8M | $149.8M | ||
| Q3 24 | $64.5M | $125.6M | ||
| Q2 24 | $66.1M | $136.6M | ||
| Q1 24 | $11.7M | $129.7M |
自由现金流率MBCRVTY
| Q4 25 | 8.1% | 21.0% | ||
| Q3 25 | 5.7% | 17.2% | ||
| Q2 25 | 9.1% | 16.0% | ||
| Q1 25 | -6.2% | 16.9% | ||
| Q4 24 | 10.3% | 20.5% | ||
| Q3 24 | 9.0% | 18.4% | ||
| Q2 24 | 9.8% | 19.7% | ||
| Q1 24 | 1.8% | 20.0% |
资本支出强度MBCRVTY
| Q4 25 | 5.3% | 2.6% | ||
| Q3 25 | 2.3% | 2.6% | ||
| Q2 25 | 2.5% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 6.9% | 3.4% | ||
| Q3 24 | 2.3% | 3.3% | ||
| Q2 24 | 1.7% | 3.2% | ||
| Q1 24 | 1.1% | 2.7% |
现金转化率MBCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 3.06× | 2.97× | ||
| Q2 25 | 2.27× | 2.49× | ||
| Q1 25 | -2.36× | 3.03× | ||
| Q4 24 | 8.22× | 1.84× | ||
| Q3 24 | 2.78× | 1.57× | ||
| Q2 24 | 1.71× | 2.87× | ||
| Q1 24 | 0.50× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MBC
| Dealers | $345.7M | 54% |
| Retail | $220.0M | 34% |
| Builders | $78.9M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
